WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 534985
CAS#: 15539-44-3
Description: C 338 is a bioactive chemical.
MedKoo Cat#: 534985
Name: C 338
CAS#: 15539-44-3
Chemical Formula: C17H20Cl2N4O2
Exact Mass: 382.0963
Molecular Weight: 383.273
Elemental Analysis: C, 53.27; H, 5.26; Cl, 18.50; N, 14.62; O, 8.35
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: C 338; C-338; C338
IUPAC/Chemical Name: 1,2-Ethanediamine, N,N-dimethyl-N'-(2-nitro-9-acridinyl)-, dihydrochloride
InChi Key: VVYQKKKUMWXTCG-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H18N4O2.2ClH/c1-20(2)10-9-18-17-13-5-3-4-6-15(13)19-16-8-7-12(21(22)23)11-14(16)17;;/h3-8,11H,9-10H2,1-2H3,(H,18,19);2*1H
SMILES Code: O=[N+](C1=CC2=C(NCCN(C)C)C3=CC=CC=C3N=C2C=C1)[O-].[H]Cl.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 383.273 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Vivacqua A, Sebastiani A, Miglietta AM, Rigiracciolo DC, Cirillo F, Galli GR, Talia M, Santolla MF, Lappano R, Giordano F, Panno ML, Maggiolini M. miR-338-3p Is Regulated by Estrogens through GPER in Breast Cancer Cells and Cancer- Associated Fibroblasts (CAFs). Cells. 2018 Nov 9;7(11):203. doi: 10.3390/cells7110203. PMID: 30423928; PMCID: PMC6262471.
2: Liang Y, Xu X, Wang T, Li Y, You W, Fu J, Liu Y, Jin S, Ji Q, Zhao W, Song Q, Li L, Hong T, Huang J, Lyu Z, Ye Q. The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis. Cell Death Dis. 2017 Jul 13;8(7):e2928. doi: 10.1038/cddis.2017.325. PMID: 28703807; PMCID: PMC5550870.
3: Niu Q, Liu Z, Gao J, Wang Q. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B. Yonsei Med J. 2019 Dec;60(12):1146-1156. doi: 10.3349/ymj.2019.60.12.1146. PMID: 31769245; PMCID: PMC6881712.
4: Zhang R, Shi H, Ren F, Feng W, Cao Y, Li G, Liu Z, Ji P, Zhang M. MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways. J Exp Clin Cancer Res. 2019 Dec 16;38(1):494. doi: 10.1186/s13046-019-1494-3. PMID: 31842953; PMCID: PMC6916056.
5: Qian Q, Zhang J, He FP, Bao WX, Zheng TT, Zhou DM, Pan HY, Zhang H, Zhang XQ, He X, Sun BG, Luo BY, Chen C, Peng GP. Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer's disease. FASEB J. 2019 Mar;33(3):4404-4417. doi: 10.1096/fj.201801846R. Epub 2018 Dec 21. PMID: 30576233; PMCID: PMC6404576.
6: Lu R, Yang Z, Xu G, Yu S. miR-338 modulates proliferation and autophagy by PI3K/AKT/mTOR signaling pathway in cervical cancer. Biomed Pharmacother. 2018 Sep;105:633-644. doi: 10.1016/j.biopha.2018.06.024. Epub 2018 Jun 10. PMID: 29898430.
7: Wang LG, Huangfu XQ, Tao B, Zhong GJ, Le ZD. Serum tenascin-C predicts severity and outcome of acute intracerebral hemorrhage. Clin Chim Acta. 2018 Jun;481:69-74. doi: 10.1016/j.cca.2018.02.033. Epub 2018 Feb 27. PMID: 29499198.
8: Long J, Luo J, Yin X. MiR-338-5p promotes the growth and metastasis of malignant melanoma cells via targeting CD82. Biomed Pharmacother. 2018 Jun;102:1195-1202. doi: 10.1016/j.biopha.2018.03.075. Epub 2018 Apr 10. PMID: 29710538.
9: Song B, Lin HX, Dong LL, Ma JJ, Jiang ZG. MicroRNA-338 inhibits proliferation, migration, and invasion of gastric cancer cells by the Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1290-1296. doi: 10.26355/eurrev_201803_14470. PMID: 29565486.
10: Menon BR, Menon N, Fisher K, Rigby SE, Leys D, Scrutton NS. Glutamate 338 is an electrostatic facilitator of C-Co bond breakage in a dynamic/electrostatic model of catalysis by ornithine aminomutase. FEBS J. 2015 Apr;282(7):1242-55. doi: 10.1111/febs.13215. Epub 2015 Feb 12. PMID: 25627283; PMCID: PMC4413051.
11: Liu J, Cao L, Feng Y, Li Y, Li T. MiR-338-3p inhibits TNF-α-induced lipogenesis in human sebocytes. Biotechnol Lett. 2017 Sep;39(9):1343-1349. doi: 10.1007/s10529-017-2369-3. Epub 2017 Jun 9. PMID: 28597147.
12: Cao R, Shao J, Hu Y, Wang L, Li Z, Sun G, Gao X. microRNA-338-3p inhibits proliferation, migration, invasion, and EMT in osteosarcoma cells by targeting activator of 90 kDa heat shock protein ATPase homolog 1. Cancer Cell Int. 2018 Apr 2;18:49. doi: 10.1186/s12935-018-0551-x. PMID: 29618948; PMCID: PMC5879792.
13: Sun F, Yu M, Yu J, Liu Z, Zhou X, Liu Y, Ge X, Gao H, Li M, Jiang X, Liu S, Chen X, Guan W. miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B. Cell Death Dis. 2018 May 1;9(5):522. doi: 10.1038/s41419-018-0611-0. PMID: 29743567; PMCID: PMC5943282.
14: Zheng J, Luo J, Zeng H, Guo L, Shao G. 125I suppressed the Warburg effect viaregulating miR-338/PFKL axis in hepatocellular carcinoma. Biomed Pharmacother. 2019 Nov;119:109402. doi: 10.1016/j.biopha.2019.109402. Epub 2019 Sep 9. PMID: 31514072.
15: Zhuang Y, Dai J, Wang Y, Zhang H, Li X, Wang C, Cao M, Liu Y, Ding J, Cai H, Zhang D, Wang Y. MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition. Am J Transl Res. 2016 Jul 15;8(7):3206-13. PMID: 27508042; PMCID: PMC4969458.
16: Dou L, Wang S, Sun L, Huang X, Zhang Y, Shen T, Guo J, Man Y, Tang W, Li J. Mir-338-3p Mediates Tnf-A-Induced Hepatic Insulin Resistance by Targeting PP4r1 to Regulate PP4 Expression. Cell Physiol Biochem. 2017;41(6):2419-2431. doi: 10.1159/000475912. Epub 2017 May 3. PMID: 28467989.
17: Kos A, de Mooij-Malsen AJ, van Bokhoven H, Kaplan BB, Martens GJ, Kolk SM, Aschrafi A. MicroRNA-338 modulates cortical neuronal placement and polarity. RNA Biol. 2017 Jul 3;14(7):905-913. doi: 10.1080/15476286.2017.1325067. Epub 2017 May 11. PMID: 28494198; PMCID: PMC5546544.
18: Teng L, Meng R. Long Non-Coding RNA MALAT1 Promotes Acute Cerebral Infarction Through miRNAs-Mediated hs-CRP Regulation. J Mol Neurosci. 2019 Nov;69(3):494-504. doi: 10.1007/s12031-019-01384-y. Epub 2019 Jul 24. PMID: 31342266.
19: Hugon J, Mouton-Liger F, Cognat E, Dumurgier J, Paquet C. Blood-Based Kinase Assessments in Alzheimer's Disease. Front Aging Neurosci. 2018 Nov 14;10:338. doi: 10.3389/fnagi.2018.00338. PMID: 30487744; PMCID: PMC6246745.
20: Stasiak M, Tymoniuk B, Stasiak B, Lewiński A. The Risk of Recurrence of Subacute Thyroiditis Is HLA-Dependent. Int J Mol Sci. 2019 Mar 3;20(5):1089. doi: 10.3390/ijms20051089. PMID: 30832406; PMCID: PMC6429176.
